Yumeng Zhang

Dr. Yumeng Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
YLYurong Li
Yurong Li
QQQin Qin
Qin Qin
YZYumeng Zhang
Yumeng Zhang
YCYuandong Cao
Yuandong Cao
Gliomas are the most common primary malignant brain tumors in adults. The fifth edition of the WHO Classification of Tumors of the Central Nervous System, published in 2021, provided molecular and practical approaches to CNS tumor taxonomy. Currently, molecular features are essential for differentiating the histological subtypes of gliomas, and recent studies have emphasized the importance of isocitrate dehydrogenase (IDH) mutations in stratifying biologically distinct subgroups of gliomas. IDH plays a significant role in gliomagenesis, and the association of IDH status with prognosis is very clear. Recently, there has been much progress in conventional MR imaging (cMRI), advanced MR imaging (aMRI), and radiomics, which are widely used in the study of gliomas. These advances have resulted in an improved correlation between MR signs and IDH mutation status, which will complement the prediction of the IDH phenotype. Although imaging cannot currently substitute for genetic tests, imaging findings have shown promising signs of diagnosing glioma subtypes and evaluating the efficacy and prognosis of individualized molecular targeted therapy. This review focuses on the correlation between MRI and MRI-based radiomics and IDH gene-phenotype prediction, discussing the value and application of these techniques in the diagnosis and evaluation of the prognosis of gliomas.


1 August 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
GCGuanhua Chen
Guanhua Chen
DLDi Liu
Di Liu
XDXiaoke Di
Xiaoke Di
SZShu Zhou
Shu Zhou
YZYumeng Zhang
Yumeng Zhang
XGXiaolin Ge
Xiaolin Ge
Background: Against the backdrop of esophageal cancer’s high global incidence, the dominant role of esophageal squamous cell carcinoma (ESCC) with poor prognosis, limited surgical opportunities, and the American Joint Committee on Cancer (AJCC) staging system’s insufficiency, there is an urgent need to develop a prognostic nomogram for ESCC patients undergoing chemoradiotherapy. The purpose of this study was to establish a clinical nomogram for effectively predicting overall survival (OS) for patients with non-operated ESCC after definitive chemoradiotherapy. Methods: A total of 869 patients diagnosed with ESCC from 2010 to 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. The nomogram was developed based on independent predictors determined by multivariate Cox regression analyses. Additional external validation was conducted on 318 ESCC patients enrolled from The First Affiliated Hospital of Nanjing Medical University. The receiver operating characteristic curve analysis and calibration plot were utilized to assess the predictive discriminative ability and reliability of the nomogram in both the training cohort and external validation cohort. The clinical practicability was evaluated by decision curve analysis and further comparing the novel model and the eighth edition of the American Joint Committee on Cancer (AJCC) staging system. Results: The multivariate analysis of the training cohort suggested that age, sex, tumor site, tumor size, clinical T stage, clinical N stage were significantly associated with OS and were all incorporated into the nomogram. The results suggested that the novel nomogram performed well with good discrimination and agreement and exhibited more optimal clinical benefits than AJCC 8th staging system. Meanwhile, an online web-server based on the new nomogram was developed for convenient clinical practice. Conclusions: The prognostic nomogram developed in this study demonstrates favorable predictive performance for survival outcomes in ESCC patients receiving definitive chemoradiotherapy. Its discriminative ability, consistency, and clinical benefits surpass those of the AJCC 8th Edition staging system. Additionally, a convenient online tool for the nomogram has been developed. This model can objectively quantify patients’ survival risks, providing critical reference for the formulation of individualized treatment strategies and possessing clinical application value.